Advertisement

Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 4953 | Ordered by Date (descending)
1 2 3 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cognate BioServices–Charles River: investment, 202102– acquisition $875m in cash by Charles River ANNOUNCED 2021-02-17
Thermo Fisher–Sidis: cell sorting technology, 202102 acquisition cell sorting assets incl Bigfoot Spectral Cell Sorter + 40 employees from Propel Labs 2021-02-17
WuXi PharmaTech–Quanterix: biomarker services, 202102– collab establishment Simoa Joint Lab at WuXI AppTec’s Shanghai facility using HD-X Analyzers 2021-02-12
Ensoma–1AB Media: public relations, 202102 service existent by 1AB Media 2021-02-11
Ensoma–5AM Ventures: investment, 202102 financing round Series A totalling $70m incl existing co-founder + seed + lead investor 5AM Ventures 2021-02-11
Ensoma–F-Prime: investment, 202102 financing round Series A totalling $70m incl co-investor F-Prime Capital 2021-02-11
Ensoma–SEVERAL: investment, 202102 financing round Series A $70m led by existing co-founder + seed investor 5AM Ventures 2021-02-11
Ensoma–Takeda: investment, 202102 financing round Series A totalling $70m incl $10m from co-investor Takeda Ventures in connection with collab 2021-02-11
NexImmune–PNC Financial Services: public relations, 202102 service existent IR by Solebury Trout 2021-02-11
NexImmune–Sam Brown: public relations, 202102 service existent by Sam Brown Inc 2021-02-11
NexImmune–SEVERAL: investment, 202102 IPO $110m+$16.5m with 6.47m+971k shares common stock at $17/share at Nasdaq Global Market 2021-02-11
Sophia Genetics–Gilmartin Group: public relations, 202102 service existent Gilmartin Group is investor contact 2021-02-11
BigHat Biosciences–8VC: investment, 202102 financing round Series A totalling $19m incl exisiting + co-investor 8VC 2021-02-10
BigHat Biosciences–AME Cloud Ventures: investment, 202102 financing round Series A totalling $19m incl exisiting + co-investor AME Cloud Ventures 2021-02-10
BigHat Biosciences–Andreessen Horowitz: investment, 202102 financing round Series A totalling $19m incl lead investor a16z 2021-02-10
BigHat Biosciences–Innovation Endeavors: investment, 202102 financing round Series A totalling $19m incl exisiting + co-investor Innovation Endeavors 2021-02-10
BigHat Biosciences–SEVERAL: investment, 202102 financing round Series A $19m led by Andreessen Horowitz 2021-02-10
Pacific Biosciences–SoftBank: credit, 202102–202802 senior convertible notes $900m due 2028 with 1.5% interest/year 2021-02-10
SpyBiotech–Alphabet: investment, 202102 financing round Series A totalling $32.5m incl existing + co-investor GV 2021-02-10
SpyBiotech–Braavos Investment Advisors: investment, 202102 financing round Series A totalling $32.5m incl new + lead investor Braavos 2021-02-10
SpyBiotech–Oxford Investment Consultants: investment, 202102 financing round Series A totalling $32.5m incl new + co-investor OIC 2021-02-10
SpyBiotech–SEVERAL: investment, 202102 financing round Series A $32.5m led by new investor Braavos Investment Advisers 2021-02-10
SpyBiotech–United Kigdom (govt): investment, 202102 financing round Series A totalling $32.5m incl Future Fund converting prior convertible loan 2021-02-10
SpyBiotech–Univ Oxford: investment, 202102 financing round Series A totalling $32.5m incl existing + co-investor Oxford Sciences Innovation 2021-02-10
Adagene–6 Degrees Communications: public relations, 202102 service existent media relations by 6 Degrees 2021-02-09
Adagene–SEVERAL: investment, 202102 US IPO $140m+$21m with 7.4mm+1.1m ADSs at $19/ADS at Nasdaq Global Market 2021-02-09
Vor Biopharma–SEVERAL: investment, 202102 IPO $176.9m+$25.5m with 9.8m+1.5m common shares at $18/share 2021-02-05
PepGen–Verge Scientific Communications: public relations, 202102 service existent by Verge 2021-02-04
Abingworth–Huntsworth: public relations, 202102 service existent by Citigate Dewe Rogerson 2021-02-03
Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund 2021-02-03
GW Pharmaceuticals–Jazz Pharmaceuticals: investment, 202102– acquisition $7.2b at $220/ADS with $200 in cash + $20 in ordinary shares ANNOUNCED 2021-02-03
Landos Biopharma–PNC Financial Services: public relations, 202011 service existent PR + IR by Solebury Trout 2021-02-03
Landos Biopharma–SEVERAL: investment, 202102 IPO $100m+$15m with 6.25m+937.5k shares common stock at $16/share at Nasdaq Global Select Market 2021-02-03
Quanterix–SEVERAL: investment, 202102 public offering $250m+$37.5m with 3.6m+535k shares common stock at $70/share with full overallotment 2021-02-03
Carisma Therapeutics–Cevec: cell line technology, 202102– license €na for use of CAP technology to produce adenovirus vectors for cancer cell therapy 2021-02-02
Cellino–8VC: investment, 202102 seed financing round $16m incl co-investor 8VC 2021-02-01
Cellino–Humboldt Fund: investment, 202102 seed financing round $16m incl co-investor Humboldt Fund 2021-02-01
Cellino–Khosla Ventures: investment, 202102 seed financing round $16m incl co-lead investor Khosla Ventures 2021-02-01
Cellino–MIT: investment, 202102 seed financing round $16m incl co-lead investor The Engine 2021-02-01
Cellino–SEVERAL: investment, 202102 seed financing round $16m from The Engine + Khosla Ventures + Humboldt Fund + 8VC 2021-02-01
Exelixis–Adagene: antibody technology, 202102– collab + license $11m upfront + milestones + royalties using SAFEbody techn to mask MAbs for ADCs et al 2021-02-01
Avacta–Adeptrix: MS-based SARS-CoV-2 test, 202101 collab existent developm of BAMS SARS-CoV-2 assay for research + IVD 2021-01-28
Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test 2021-01-28
BiondVax–SEVERAL: investment, 202101– Pulbic Offering $12m+$1.8m with 2.4m+365k ADSs at $4.95/ADS 2021-01-28
Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund 2021-01-28
Lauxera Capital–SEVERAL: investment, 2020–2021 launch of €100m fund incl investors Bpifrance + Covéa + Téthys + CNP et al 2021-01-27
Encodia–Alexandria Real Estate: investment, 202101 financing round Series C totalling $75m incl new + co-investor Alexandria Venture Investments 2021-01-26
Encodia–Alphabet: investment, 202101 financing round Series C totalling $75m incl new + co-investor GV 2021-01-26
Encodia–ARCH Venture: investment, 202101 financing round Series C totalling $75m incl existing + co-investor ARCH Venture Partners 2021-01-26
Encodia–Biomatics Capital: investment, 202101 financing round Series C totalling $75m incl existing + co-investor Biomatics Capital 2021-01-26
Encodia–Decheng Capital: investment, 202101 financing round Series C totalling $75m incl existing + co-investor Decheng Capital 2021-01-26
Encodia–Deerfield: investment, 202101 financing round Series C totalling $75m incl co-lead investor Deerfield Management 2021-01-26
Encodia–Nan Fung: investment, 202101 financing round Series C totalling $75m incl existing + co-investor Nan Fung Life Sciences 2021-01-26
Encodia–Northpond Ventures: investment, 202101 financing round Series C totalling $75m incl co-lead investor Northpond Ventures 2021-01-26
Encodia–SEVERAL: investment, 202101 financing round Series C $75m led by Northpond Ventures + Deerfield Management 2021-01-26
Encodia–Tao Capital Partners: investment, 202101 financing round Series C totalling $75m incl existing + co-investor Tao Capital Partners 2021-01-26
GeneQuine–Pacira BioSciences: credit, 202101 convertible loans totalling €2.75m from Pacira + Samum Vermögensverwaltungs GmbH 2021-01-26
GeneQuine–Pacira BioSciences: investment, 202101 financing round Series A totalling €5.4m incl lead investor Pacira BioSciences 2021-01-26
GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences 2021-01-26
Mobilion–Protein Metrics: mass spectrometry software, 202101– collab integration of Byos software suit with Mobilion HRIM MS system 2021-01-26
AgeX Therapeutics–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital 2021-01-25
Cellvie–Forever Healthy: investment, 202101 seed financing round totalling $5m incl lead investor Kizoo Technology Capital 2021-01-25
Cellvie–SEVERAL: investment, 202101 seed financing round $5m led by Kizoo Technology Capital 2021-01-25
CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share 2021-01-25
Elevian–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital 2021-01-25
FoxBio–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital 2021-01-25
Lift BioSciences–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital 2021-01-25
Maia Biotechnology–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital 2021-01-25
Oisin Biotechnologies–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital 2021-01-25
TScan Therapeutics–6 Dimensions Capital: investment, 202101 financing round Series C totalling $100m incl existing investor 6 Dimensions Capital 2021-01-25
TScan Therapeutics–Alphabet: investment, 202101 financing round Series C totalling $100m incl existing investor GV 2021-01-25
TScan Therapeutics–Argot Partners: public relations, 202101 service existent media relations + IR by Argot Partners 2021-01-25
TScan Therapeutics–Bessemer Venture: investment, 202101 financing round Series C totalling $100m incl existing investor Bessemer Venture Partners 2021-01-25
TScan Therapeutics–BlackRock: investment, 202101 financing round Series C totalling $100m incl new investor funds + accounts managed by Black Rock 2021-01-25
TScan Therapeutics–Longwood Fund: investment, 202101 financing round Series C totalling $100m incl founding + existing investor Longwood Fund 2021-01-25
TScan Therapeutics–Novartis: investment, 202101 financing round Series C totalling $100m incl existing investor Novartis Venture Fund 2021-01-25
TScan Therapeutics–Pitango: investment, 202101 financing round Series C totalling $100m incl existing investor Pitango HealthTech 2021-01-25
TScan Therapeutics–RA Capital: investment, 202101 financing round Series C totalling $100m incl new investor RA Capital Management 2021-01-25
TScan Therapeutics–SEVERAL: investment, 202101 financing round Series C $100m incl new investors Black Rock + RA Capital 2021-01-25
Turn.Bio–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital 2021-01-25
Servier–MiNA Therapeutics: saRNA therapeutics, 202101– collab research + license option for saRNA therapeutics for neurological diaseses 2021-01-21
Biophytis–SEVERAL: investment, 202101– US IPO of ADSs up to $14.5m at Nasdaq 2021-01-20
Neuvogen–10K Partners: public relations, 202101 service existent by 10K Partners 2021-01-20
ConserV Bioscience–Optimum Strategic Communications: public relations, 202101 service existent by Optimum 2021-01-19
ConserV Bioscience–United States (govt): coronavirus vaccine, 202101– collab developm broad spectrum coronvirus vaccine using NLP technology from LLNL 2021-01-19
CoviCept Therapeutics–Forbion: investment, 202101 seed investment $2.3 from Forbion 2021-01-19
Merus–SEVERAL: investment, 202101 public offering $120m+$18m with 4.85m+727.3k common shares at $24.75/share 2021-01-19
Mesa Biotech–Thermo Fisher: investment, 202101– acquisition $450m cash upfront + $100m cash milestones of Mesa Biotech Inc by Thermo Fisher 2021-01-19
Slate Bio–Epidarex Capital: investment, 202101 seed financing round totalling $1.75m incl lead investor Epidarex Capital 2021-01-19
Slate Bio–SEVERAL: investment, 202101 seed financing round $1.75m led by Epidarex Capital 2021-01-19
Novasep–Thermo Fisher: investment, 202101 acquisition €725m in cash of viral vector manufacturing business Henogen SA in Belgium by Thermo Fisher 2021-01-15
NewAmsterdam Pharma–SEVERAL: investment, 202101 financing round Series A €160m co-led by Morningside Ventures + Ascendant BioCapital 2021-01-14
IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments 2021-01-13
Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors 2021-01-13
Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share 2021-01-12
AltPep–Alexandria Real Estate: investment, 202101 fianncing round Series A totalling $23.15m inc significant participation by Alexanria VI 2021-01-12
AltPep–Matrix Capital Management: investment, 202101 fianncing round Series A totalling $23.15m inc lead investor Matrix Capital Mgt 2021-01-12
AltPep–SEVERAL: investment, 202101 fianncing round Series A $23.15m led by Matrix Capital Mgt with significant participation by Alexandria VI 2021-01-12
Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based 2021-01-11
Boehringer–Alphabet: quantum computing, 202101–202312 collab research + implementation of quantum computing in pharma RnD with Google Quantum AI 2021-01-11
1 2 3 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] Fighting Customers 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px

» top